JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 16, 2007; DOI: 10.1124/jpet.106.119057


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.119057v1
321/2/810    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackson, E. K.
Right arrow Articles by Mi, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, E. K.
Right arrow Articles by Mi, Z.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ADENOSINE 5'-PHOSPHATE


Received for publication January 3, 2007.
Revised February 12, 2007.
Accepted for publication February 12, 2007.

CHARACTERIZATION OF RENAL ECTO-PHOSPHODIESTERASE

Edwin K. Jackson 1*, Jin Ren 1, Lefteris C. Zacharia 1, Zaichuan Mi 1

1 University of Pittsburgh

* Address correspondence to: E-mail: edj{at}pitt.edu

Abstract

In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase and metabolism of AMP to adenosine by ecto-5'-nucleotidase. Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized. We administered cAMP (10 µmol/L in the perfusate) to 12 different groups of perfused kidneys. AMP was measured in perfusate using ion trap mass spectrometry. In control kidneys (n=17), basal renal secretion rate of AMP was 0.49 ± 0.08 and increased to 3.0 ± 0.2 nmoles AMP per gram kidney weight per min during adminstration of cAMP. A broad spectrum PDE inhibitor (1,3-isobutyl-1-methylxanthine, 300 µmol/L, n=6) and an ecto-phosphodiestease inhibitor (1,3-dipropyl-8-sulfophenylxanthine, 1 mmol/L, n=6) significantly attenuated cAMP-induced AMP secretion by 60% and 74%, respectively. Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 µmol/L), PDE2 (erythro-9-(2-hydroxy-3-nonyl)-adenine, 30 µmol/L), PDE3 (milrinone, 10 µmol/L; cGMP, 10 µmol/L), PDE4 (RO 20-1724, 100 µmol/L), PDE5 and PDE6 (zaprinast, 30 µmol/L) and PDE7 (BRL-50481, 10 µmol/L) did not alter renal ecto-phosphodiesterase activity. Administration of a concentration (100 µmol/L) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%). However, a lower concentration of dipyridamole (3 µmol/L) that blocks PDE9, PDE10 and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity. These data support the conclusion that renal ecto-phosphodiesterase activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10 or PDE11, and is inhibited by high concentrations of dipyridamole. Ecto-phosphodiesterase has some pharmacological characteristics similar to PDE8.


Key words: AMP, adenosine, cAMP, cAMP-adenosine pathway, ecto-5'-nucleotidase, ecto-phosphodiesterase


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson and Z. Mi
Regulation of Renal Ectophosphodiesterase by Protein Kinase C and Sodium Diet
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 210 - 216.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.